Synthorx, Inc. announced that preclinical data highlighting THOR-809 will be presented at the American College of Rheumatology (ACR) Annual Meeting taking place in Atlanta from November 8, 2019. Marcos E. Milla, Ph.D., chief scientific officer of the company, will present research supporting the development of THOR-809, the company’s lead Synthorin™ for the treatment of autoimmune disorders. THOR-809 is a site-specific, covalently-pegylated interleukin-2 (IL-2) variant that was discovered using Synthorx’ first-of-its-kind Expanded Genetic Alphabet platform. Preclinical models showed that the compound selectively expands regulatory T cells, without activating and expanding effector T or natural killer cells.